NCT07912086 31P-MRS Myocardial Energetic Phenotyping and Prognosis Across the Cardiac Disease Spectrum
| NCT ID | NCT07912086 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Chinese Academy of Medical Sciences, Fuwai Hospital |
| Condition | Cardiomyopathies |
| Study Type | OBSERVATIONAL |
| Enrollment | 1,000 participants |
| Start Date | 2025-08-01 |
| Primary Completion | 2030-09-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 1,000 participants in total. It began in 2025-08-01 with a primary completion date of 2030-09-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The study is designed to establish a comprehensive myocardial energetic phenotype across a broad spectrum of cardiovascular diseases using phosphorus-31 magnetic resonance spectroscopy (31P-MRS). And the study plans to enroll 1,000 participants, comprising healthy volunteers and patients with diverse cardiac conditions. Target cohorts primarily encompass heart failure syndromes and various cardiomyopathies, with a particular focus on non-ischemic and hypertrophic phenotypes, as well as ischemic and other structural etiologies. By integrating 31-MRS with multiparametric standard CMR, this study aims to map disease-specific metabolic signatures. The primary outcome measure is the myocardial PCr/ATP ratio, serving as a direct in vivo marker of energetic impairment. Furthermore, the study aims to explore the coupling between metabolic phenotypes and structural remodeling (tissue characterization), mechanical dysfunction, and systemic clinical biomarkers. Crucially, the study will evaluate the prognostic value of these energetic phenotypes in predicting clinical outcomes, ultimately providing novel insights into the pathophysiology and risk stratification of cardiomyopathies and heart failure.
Eligibility Criteria
Inclusion Criteria: * Age \>= 18 years * Healthy volunteers, OR * Clinical diagnosis of cardiac disease, including non-ischemic cardiomyopathy (hypertrophic, amyloid, or inflammatory), ischemic cardiomyopathy, hypertensive heart disease, or valvular heart disease, OR * Inherited metabolic cardiomyopathies * Able to undergo CMR examination and provide written informed consent Exclusion Criteria: \* Any contraindication to CMR examination
Frequently Asked Questions
Who can join the NCT07912086 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Cardiomyopathies. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07912086 currently recruiting?
Yes, NCT07912086 is actively recruiting participants. Visit ClinicalTrials.gov or contact Chinese Academy of Medical Sciences, Fuwai Hospital to inquire about joining.
Where is the NCT07912086 trial being conducted?
This trial is being conducted at Beijing, China.
Who is sponsoring the NCT07912086 clinical trial?
NCT07912086 is sponsored by Chinese Academy of Medical Sciences, Fuwai Hospital. The trial plans to enroll 1,000 participants.